Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,871 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT06959641RecruitingPhase 2
XL092 for advanced thyroid cancer that no longer responds to radioactive iodine
This trial is testing a new oral medication, XL092, for people with advanced thyroid cancer that has stopped responding to radioactive iodine therapy. The goal is to see if XL092 can slow or stop the cancer from growing.
Torrance, CaliforniaAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Hot Springs, ArkansasAges 18 years+ - NCT06241846RecruitingPhase 2
Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Hefei, AnhuiAges 18 years+ - NCT05956639RecruitingPhase 3
Rezvilutamide with ADT and chemo: shorter versus longer treatment
This Phase 3 trial compares two lengths of rezvilutamide treatment when given with hormone therapy (ADT) and chemotherapy for men with advanced prostate cancer. It aims to find which treatment duration works best and is safest to help control the cancer.
Nanjing, JiangsuAges 18 years+ - NCT06031805Recruiting
Real-world study of olaparib for prostate cancer
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
AmiensAges 18 years+ - NCT05649943Recruiting
New prostate cancer treatment plus local therapy for metastatic cases
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
Milan, LombardyAges 18 years+ - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT03851640RecruitingPhase 3
Study drug for advanced prostate cancer that kept spreading despite standard treatments
This Phase 3 study tests HC-1119 soft capsules in men with metastatic castration-resistant prostate cancer—cancer that keeps progressing even when testosterone is blocked. It aims to see whether the drug works better than expected and is safe, especially after prior treatments like abiraterone and/or docetaxel.
ShanghaiAges 18 years+ - NCT06529549Recruiting
Organoid drug test for advanced prostate cancer
This trial uses a lab test on a tiny sample of your tumor (called an organoid) to find which drug might work best for your advanced prostate cancer. It's for men whose cancer has stopped responding to hormone therapy and got worse after first treatment.
Guangzhou, GuangdongAges 18–75 - NCT06673628RecruitingPhase 2
Pembrolizumab plus lenvatinib for skin angiosarcoma
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
KashiwaAges 18–85 - NCT05116579Recruiting
Using blood DNA tests to track PARP inhibitor response
This trial uses a blood test (circulating tumor DNA) to see whether PARP inhibitors are working for certain men with advanced prostate cancer. It may help predict which treatment responses are likely and monitor changes over time.
Guangzhou, GuangdongAges 18–75 - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06492122RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT06155084RecruitingPhase 1/Phase 2
HP518 for advanced prostate cancer that has spread
This trial tests an oral drug called HP518 for men with a specific genetic change in their prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The goal is to see if HP518 can control the cancer.
Hefei, AnhuiAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06023212RecruitingPhase 1/Phase 2
Tranexamic acid to prevent bleeding in spine surgery for lung cancer
This trial tests if a medicine called tranexamic acid can help reduce bleeding during surgery for lung cancer that has spread to the spine. It may be an option if you have a single tumor in your spine and are having separation surgery.
Hangzhou, ZhejiangAges 10–80 - NCT07093866RecruitingPhase 2
Targeted drug combo for advanced prostate cancer
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
Nanjing, JiangsuAges 18–75 - NCT07100704RecruitingPhase 2
Nivolumab for recurrent olfactory neuroblastoma
This trial tests the drug nivolumab for people with a rare nasal tumor (olfactory neuroblastoma) that has come back or spread and cannot be treated with surgery or radiation. You must have already tried chemotherapy and it stopped working. The goal is to see if nivolumab can shrink the tumor or slow its growth.
Kashiwa, ChibaAges 18 years+ - NCT05762536RecruitingPhase 2
Docetaxel or cabazitaxel with or without darolutamide
This Phase 2 study tests whether adding darolutamide to either docetaxel or cabazitaxel helps treat men with advanced, progressing prostate cancer. It’s for cancers that have already grown despite hormone-blocking tablets (ARSi).
RotterdamAges 18 years+ - NCT07441174RecruitingPhase 1/Phase 2
A study of two drugs for KRAS G12D tumors
This trial tests two experimental drugs (IN10018 and RNK08954) together for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if this combination can shrink tumors when standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06514521Recruiting
Study of Pluvicto for prostate cancer in Korea
This study is for men with prostate cancer who are being treated with or are scheduled to receive the drug Pluvicto in South Korea. It aims to track real-world results and safety.
Seongnam-si, Gyeonggi-doAges 18–100 - NCT07007910RecruitingPhase 1
Study of HSK46575 for advanced prostate cancer
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
Chengdu, SichuanAges 18 years+
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,871 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.